Agile Therapeutics (NASDAQ:AGRX) Trading 7.3% Higher

Agile Therapeutics Inc (NASDAQ:AGRX) traded up 7.3% during mid-day trading on Monday . The stock traded as high as $1.20 and last traded at $1.18, 1,445,857 shares were traded during trading. An increase of 200% from the average session volume of 481,883 shares. The stock had previously closed at $1.10.

Several equities analysts have recently issued reports on the company. ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded Agile Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Agile Therapeutics has a consensus rating of “Buy” and a consensus target price of $3.45.

The stock has a market capitalization of $53.71 million, a price-to-earnings ratio of -2.04 and a beta of 0.38. The business has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.32.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Research analysts anticipate that Agile Therapeutics Inc will post -0.37 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGRX. Acadian Asset Management LLC increased its holdings in shares of Agile Therapeutics by 7.9% in the second quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock valued at $657,000 after buying an additional 32,911 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Agile Therapeutics by 27.2% in the second quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after buying an additional 36,212 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Agile Therapeutics by 2,219.3% in the second quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after buying an additional 73,238 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Agile Therapeutics by 5.6% in the second quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after buying an additional 120,403 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Agile Therapeutics by 129.8% in the second quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after buying an additional 978,672 shares in the last quarter. Hedge funds and other institutional investors own 43.73% of the company’s stock.

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Read More: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.